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MaOBJECTIVES The aim of this study was to analyze the pacemaker implantation rate (PMIR) with the new
balloon-expandable Edwards SAPIEN 3 valve (S3) and the factors associated with it.
BACKGROUND The introduction of the S3 for transcatheter aortic valve replacement (TAVR) has led to a reduction in
paravalvular regurgitation. There are, however, concerns that the new design may increase the PMIR.
METHODS The ﬁrst 206 patients treated with the S3 were compared with 371 preceding patients treated with
SAPIEN XT valves. Patients who previously underwent pacemaker or implantable cardioverter deﬁbrillator implantation
or transapical and valve-in-valve procedures were excluded from the analysis. All patients were monitored for at least
7 days. Previous and new conduction abnormalities were documented, and prosthesis implantation height was assessed
for the S3.
RESULTS There were no signiﬁcant differences in baseline characteristics between groups. The PMIR was, however,
signiﬁcantly higher for the S3 (19.1% vs. 12.2%; p ¼ 0.046). The mean implantation height was signiﬁcantly lower in
patients requiring PMI (67%/33% vs. 72%/28% aortic/ventricular stent extension, p ¼ 0.032). On multivariate regression
analysis, implantation height was the only independent predictor of PMI (odds ratio: 0.94 [95% conﬁdence interval:
0.90 to 0.99]; p ¼ 0.009). It increased from 68%/32% to 75%/25% when comparing the ﬁrst with the second half
of S3 implantations (p < 0.0001). This change was associated with a signiﬁcant decrease in PMIR from 25.9% to 12.3%
(p ¼ 0.028), no longer different from the XT valve (12.2%).
CONCLUSIONS The PMIR after TAVR is higher with the S3 than with the XT and is independently associated with
the implantation height. This increase in the PMIR may be avoided by intending an aortic stent extension >70%.
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ABBR EV I A T I ON S
AND ACRONYMS
AV = atrioventricular
AVCA = atrioventricular
conduction abnormality
LVOT = left ventricular
outﬂow tract
MDCT = multidetector
computed tomography
PMIR = pacemaker
implantation rate
PPM = permanent pacemaker
PPMIR = permanent pacemaker
implantation rate
PVR = paravalvular
regurgitation
ROC = receiver-operating
characteristic curve
S3 = Edwards SAPIEN 3 valve
TAVR = transcatheter aortic
valve replacement
XT = Edwards SAPIEN XT valve
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806T ranscatheter aortic valve replace-ment (TAVR) has become anaccepted treatment alternative for
severe aortic stenosis in patients at high sur-
gical risk (1,2). Atrioventricular conduction
abnormalities (AVCAs) are a common compli-
cation after TAVR (3–7) and are associated
with an increased permanent pacemaker
(PPM) implantation rate (PPMIR) (8–10). This
remains one of the concerns with this inter-
vention, particularly when considering even
lower risk patients for TAVR. In general, the
reported occurrence of AVCAs and need for
PPM implantation was markedly lower for
balloon-expandable valves than for self-
expandable valves (10–12). Studies with the
balloon-expandable Edwards SAPIEN XT
valve (XT) (Edwards Lifesciences, Irvine, Cal-
ifornia) have reported an average PPMIR of
w6% (range, from 4% to 13%) (13). The recent
introduction of the next generation of
balloon-expandable valve of the Edwards SA-PIEN family, the Edwards SAPIEN 3 valve (S3)
(Edwards Lifesciences) was suggested to lead to a
marked reduction in paravalvular regurgitation
(PVR) (14). This valve incorporates a new adaptive
external tissue seal aimed at reducing PVR and its
newly designed stent allowing for a lower delivery
proﬁle is 3 to 4 mm longer than in the XT. TheSEE PAGE 814PPMIR after TAVR with the S3 reported in the release
study of the valve was 13.3% (14), a rate higher than
usually reported with the previous generations of the
balloon-expandable valve (15). The markedly higher
PPMIR reported for the self-expanding CoreValve
(Medtronic, Minneapolis, Minnesota) (range, 24% to
33%) (10) was suggested to be caused by the design-
related extension of the stent deeper into the left ven-
tricular outﬂow tract (LVOT) (8). Higher implantation
of the valve was indeed reported to reduce the PPMIR
(16). The longer stent of the S3 that may extend deeper
into the LVOT may also result in a higher rate of
AVCAs compared with the previous valve generation.
It remains, however, currently unclear whether the
PPMIR indeed differs between S3 and XT TAVR and
which mechanisms may explain such differences.
The aim of the present study was, therefore, to
compare the PPMIR between patients undergoing
TAVR using S3 and XT valves and to identify risk fac-
tors for the development of AVCAs and need for a
PPM after S3 implantation, considering in particular
the role of the implantation height of the valve.METHODS
All patients undergoing TAVR at our institution
with the XT and the S3 between January 2010 and
January 2015 were screened. Inclusion criteria for the
ﬁnal study population were that the patients 1) did
not have a pacemaker or implantable cardioverter-
deﬁbrillator before TAVR, 2) were treated for severe
native aortic stenosis (no valve-in-valve implanta-
tion), and 3) underwent implantation via trans-
femoral access.
All patients underwent a thorough clinical and
echocardiographic evaluation before being consid-
ered for TAVR. The indication for TAVR was estab-
lished by the multidisciplinary heart team including
cardiologists and cardiac surgeons. Clinical records of
the patients were reviewed, and all relevant infor-
mation regarding AVCAs or PPM implantation before
and during implantation was collected. All patients
were monitored for 7 days after TAVR with contin-
uous electrocardiographic telemetry after implanta-
tion. Speciﬁc guidelines for PPM implantation in the
setting of TAVR are currently lacking. The decision to
implant a PPM was left to the discretion of the local
interdisciplinary team including valvular heart dis-
ease and electrophysiology experts. In order to ac-
count for possible differences in PPM implantation
threshold in the study groups, we classiﬁed the PPM
implantation into 2 groups of indications according to
current guidelines (17): the Class I/IIa indication
group of patients includes those with a “therapeutic”
indication, whereas the Class IIb indication group
includes those with “prophylactic” PPM implantation
indications. All patients underwent 12-lead electro-
cardiographic and echocardiographic evaluation
before discharge. The degree of PVR was deﬁned ac-
cording to the Valve Academic Research Consortium
criteria (18).
The implantation height in the S3 group was
analyzed by off-line evaluation of procedural ﬂuo-
roscopy. A single still frame of the pre- and post-
implantation aortic angiographies was selected for
each patient. The implantation height was assessed
quantitatively by 2 experienced investigators (G.K.
and H.B.) who were blind to the objectives of the
study. Interobserver discrepancies were resolved by
consensus. The native aortic valve annulus was
deﬁned as the connection line of the deepest points
of cusp insertions in the pre-implantation angiog-
raphy. Identiﬁcation of the same line in the post-
implantation angiography by direct comparison
was attempted. The ﬁnal stent length and the dis-
tance from the native aortic annulus to the aortic
FIGURE 1 Analysis of the Valve Implantation Height of the
Edwards SAPIEN 3 Valve
The total length (TL) of the stent (yellow arrowed line) is
assessed by measuring the distance between the 2 ends of the
stent (yellow dashed lines). The aortic length (AL) (white
arrowed line) is the distance between the aortic end of the stent
and the aortic annulus (white arrowheads). For details, see also
Methods section. The implantation height is deﬁned as the per-
centages of the stent lying in the aorta and the left ventricular
outﬂow tract.
FIGURE 2 Study Flow Chart
The ﬂowchart provides information about the included and excluded patients in
the SAPIEN 3 and SAPIEN XT groups. ICD ¼ implantable cardioverter-deﬁbrillator;
PM ¼ pacemaker; TAVR ¼ transcatheter aortic valve replacement.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 8 , 2 0 1 6 De Torres-Alba et al.
A P R I L 2 5 , 2 0 1 6 : 8 0 5 – 1 3 PM Rate in S-3: Role of Implantation Height
807end of the stent were measured. The implantation
height was expressed as the percentage of the
stent lying on the aortic and the ventricular sides
(Figure 1).
The valve size selection was at the discretion of the
operators who were aware of the multidetector
computed tomography (MDCT) size recommendation
provided by the vendor speciﬁcations. An S3 was
considered oversized when the S3 nominal area was
greater than the systolic MDCT annular area. The
percentage of oversizing (positive percentage) or
undersizing (negative percentage) was calculated
using the following formula: % oversizing ¼ (S3
nominal area/MDCT annular area  1)  100. In
addition, to further analyze a possible effect of the
sizing of the valve in the PPMIR, we also categorized
patients in the S3 group depending on the percentage
of MDCT area oversizing/undersizing in the following
categories: <0% (undersizing); 0% to 10%; 10% to
20%; and >20% (oversizing).
All patients signed an informed consent for inter-
ventional treatment and data collection allowing
intrainstitutional retrospective data analysis.STATISTICAL ANALYSIS. Quantitative data were
expressed as the mean  SD. Categorical variables
were expressed as counts and percentages. Quanti-
tative variables adjusting to a normal distribution
were compared by the Student t test. Nonnormal
variables were compared with the Wilcoxon test.
Comparison of categorical variables was performed
with the chi-square test or the Fisher exact test, as
appropriate. A multivariate regression analysis was
performed to assess for independent predictors of
PPM implantation after S3 implantation. Pearson’s
correlation was used to describe the temporal
changes in the implantation height in the S3 group
over time. The optimal value of implantation height
was assessed based on the combination between
sensitivity and speciﬁcity as measured by receiver-
operating characteristic curve analysis.
All reported p values are 2 sided, and p values
<0.05 were considered statistically signiﬁcant. Sta-
tistical analysis were performed using IBM SPSS
Statistics for Windows, Version 22.0. (IBM Corp.,
Armonk, New York). To account for a possible selec-
tion bias and therefore a possible lack of compara-
bility of the XT and S3 groups, propensity score
matching was performed using the MatchIt Package
for R (R Foundation for Statistical Computing,
Vienna, Austria) with a nearest-neighbor 1-to-1
matching method.
RESULTS
During the deﬁned study period, 206 patients un-
derwent TAVR with the S3 (recent cohort) and 371
TABLE 1 Baseline Characteristics of the Study Groups by Valve Type
SAPIEN XT Valve
(n ¼ 287)
SAPIEN 3 Valve
(n ¼ 162) p Value
Age, yrs 82.1  6.0 82.1  6.1 0.998
Male 107 (37.3) 61 (37.7) 0.938
Logistic EuroSCORE I 22.6  15.8 24.1  12.2 0.526
Previous AVCA (any) 110 (39) 50 (30.9) 0.085
First-degree AV block 57 (20.2) 28 (17.3) 0.450
Second-degree AV block
(Mobitz type I)
4 (1.4) 0 (0) 0.075
Right bundle branch block 31 (11) 9 (5.6) 0.054
Left bundle branch block 33 (11.7) 18 (11.1) 0.851
Left anterior hemiblock 9 (3.2) 4 (2.5) 0.066
Left posterior hemiblock 0 (0) 0 (0) —
Valve size, mm
23 104 (36.2) 73 (45.1) 0.020
26 147 (51.2) 61 (37.7)
29 36 (12.5) 28 (17.3)
Values are mean  SD or n (%).
AV ¼ atrioventricular; AVCA ¼ atrioventricular conduction abnormality.
TABLE 2
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Table 1.
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808patients received the XT (preceding cohort). After
exclusion of those patients with a previously
implanted pacemaker or implantable cardioverter-
deﬁbrillator (9.2% in the S3 group and 12.7% in
the XT group), transapical implantations (7.8% in
the S3 group and 10.0% in the XT group) andPost-Procedural Outcome
SAPIEN XT Valve
(n ¼ 287)
SAPIEN 3 Valve
(n ¼ 162) p Value
l mortality
an stay, 8 days)
7 (2.4) 3 (1.9) 0.686
(any) 83 (28.9) 64 (39.5) 0.022
ntation 35 (12.2) 31 (19.1) 0.046
Ia indication 30 (85.7) 29 (93.5) 0.433
indication 5 (14.3) 2 (6.5)
degree AV block 23 (8.0) 18 (11.1) 0.274
d-degree AV block
bitz type I)
2 (0.7) 0 (0) 0.538
d-degree AV block
bitz type II)
4 (1.4) 1 (0.6) 0.658
bundle branch block 6 (2.1) 4 (2.5) 0.794
undle branch block 31 (10.8) 21 (13.0) 0.492
nterior hemiblock 0 (0) 0 (0) —
-degree AV block 30 (10.5) 28 (17.3) 0.038
78 (26.1) 74 (45.3) 0.001
90 (31.8) 46 (28.6)
90 (31.8) 35 (21.7)
moderate 21 (7.4) 7 (4.3)
te 8 (2.8) 0 (0.0)
(%).
ermanent pacemaker; PVR ¼ paravalvular regurgitation; other abbreviations as invalve-in-valve procedures (4.4% in the S3 group and
2.7% in the XT group), 162 patients treated with the
S3 and 287 patients treated with the XT remained
for further analysis (Figure 2). Baseline characteris-
tics of the 2 groups are presented in Table 1. There
were no signiﬁcant differences in age, sex, baseline
risk proﬁle or pre-existing conduction abnormalities
between the 2 groups. In the XT group, the most
frequently implanted valve size was 26 mm (51.2%
vs. 37.7% in the S3 group), whereas in the S3 group,
23-mm was the most frequently used valve size
(45.1% vs. 36.2% in the XT group). This difference
in implanted valve sizes was statistically signiﬁcant
(p ¼ 0.02). Table 2 shows the post-procedural
outcome. The in-hospital mortality (all-cause mor-
tality during index procedure hospitalization) was
2.2% for the entire cohort and did not signiﬁcantly
differ between groups. The mean length of stay was
8 days.
A signiﬁcant reduction in PVR was observed in the
S3 group compared with the XT group (Table 2,
Figure 3). The percentage of patients with no PVR
increased from 26.1% to 45.5%. The percentage of
patients with mild to moderate PVR decreased from
7.4% to 4.3%. Although 2.8% of patients with XT
valves had moderate PVR, none of the S3 patients had
moderate or severe PVR.
The development of new AVCAs of any type was,
however, signiﬁcantly higher in the S3 group (39.0%
vs. 28.9%; p¼ 0.022). The PPMIR was also signiﬁcantly
higher in the S3 group (19.1% vs. 12.2%; p ¼ 0.049).
The results of the propensity score analysis were
consistent with the results of the unmatched
analysis, conﬁrming a signiﬁcant difference in the
PPMIR (12.6% in the XT group and 22.1% in the S3
group; p ¼ 0.017). Table 2 shows the speciﬁc
AVCAs that developed in both groups. Only the
development of third-degree atrioventricular (AV)
block was signiﬁcantly more frequent in the S3
group. The indication for PPM implantation in
those patients in whom new AVCAs developed was
a Class I/IIa indication in 30 patients in the XT
group (85.7% of all PM implantations in this group)
and in 29 patients (93.5% of all PM implantations
in this group) in the S3 group, with no signiﬁcant
differences between groups.
The characteristics of S3 patients with and without
a need for PPM implantation are presented in Table 3.
Patients who received a PPM after TAVR did not
signiﬁcantly differ from those without a need for a
PPM with regard to age (83.9  4.3 vs. 81.7  6.4
years; p ¼ 0.07), sex (35.5% vs. 38.2% male,
p ¼ 0.782), logistic EuroSCORE (18.4  9.0 vs. 25.6 
12.5; p ¼ 0.08), and aortic valve calcium score
FIGURE 3 Severity of Paravalvular Regurgitation in the SAPIEN 3 and SAPIEN XT Groups
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809(3,090  1,577 in the S3 group vs. 3,199  1,980 in the
XT group; p ¼ 0.77). Among pre-existing AVCAs, right
bundle branch block was signiﬁcantly more frequent
in patients who eventually required a PPM after
TAVR (16.1% vs. 3.1%; p < 0.014). Regarding proce-
dural characteristics, the mean implantation height
of the S3 was signiﬁcantly lower in patients requiring
a PPM (67%/33% vs. 72%/28% aortic/ventricular
stent extension, p ¼ 0.032 (Figure 4).
Mean area oversizing was 7.4  11.1% in the
S3 group. Undersizing was present in 42 patients
(27.8%). MDCT area oversizing percentages of 0%
to 10%, 10% to 20%, and >20% were present in
46 patients (28.4%), 46 (28.4%), and 17 (10.4%),
respectively. Mean area oversizing was 6.6  10.5%
in those patients who did not require a PPM and 10.9
 12.9% in those patients who required PPM with no
signiﬁcant difference between groups (p ¼ 0.06).
MDCT area undersizing and oversizing percentages
of <10%, 10-20%, and >20% were present in 37 pa-
tients (30.6%), 38 (31.4%), 34 (28.1%), and 12 (9.9%)
in the cohort of patients who did not require a PPM
and in 5 patients (16.7%), 8 (26.7%), 12 (40.0%), and
5 (16.7%) in the cohort of patients who required a
PPM, with no signiﬁcant differences between groups
(p ¼ 0.268).On multivariate logistic regression analysis
including the presence of a pre-existing right bundle
branch block, implantation height, valve sizing, age,
and sex, implantation height remained the only in-
dependent predictor of the need for PPM implanta-
tion (odds ratio: 0.95 [95% conﬁdence interval:
0.91 to 0.99]; p ¼ 0.025). By receiver-operating char-
acteristic curve analysis, implantation heights of 73%/
27% aortic/ventricular resulted as the best cutoff in
terms of a reduction in the PPMIR for the S3 (sensi-
tivity, 59%; speciﬁcity, 83%; area under the curve,
70.1%). The PPMIR in patients with implantation
heights of 73%/27% aortic/ventricular or more (n ¼ 77)
was 6.5% compared with 32.9% in those with an im-
plantation height <73%.
During the study period, a signiﬁcant increase in
implantation height of the S3 was observed over time
(Figure 5) (r ¼ 0.447; p < 0.001). However, the mean
area oversizing did not change signiﬁcantly over time
(r ¼ 0.11; p ¼ 0.179).
In order to analyze the inﬂuence of this observed
temporal trend of a progressively higher implantation
of the valve on the PPMIR in the S3 group, we
compared the ﬁrst 50% of patients with the second
50%. The signiﬁcant increase in the implantation
height from 68%/32% to 75%/25% aortic/ventricular
TABLE 3 Characteristics of Patients With and Without the Need for
TAVR-Related Pacemaker Implantation
No PPM Implantation
(n ¼ 131)
PPM Implantation
(n ¼ 31)
p
Value
Age, yrs 81.7  6.4 83.9  4.3 0.070
Male 50 (38.2%) 11 (35.5%) 0.782
Logistic EuroSCORE I 25.6  12.5 18.4  9.0 0.078
Previous AVCA (any) 37 (28.2) 13 (41.9) 0.138
First-degree AV block 23 (17.6) 5 (16.1) 0.850
Second-degree AV block (Mobitz type I) 0 (0) 0 (0) —
Right bundle branch block 4 (3.1) 5 (16.1) 0.014
Left bundle branch block 14 (10.7) 4 (12.9) 0.724
Left anterior hemiblock 3 (2.3) 1 (3.2) 0.576
Calcium score of the native aortic valve 3,090  1,577 3,199  1,980 0.772
Valve size (nominal diameter), mm
23 57 (43.5) 16 (51.6) 0.299
26 53 (40.5) 8 (25.8)
29 21 (16.0) 7 (22.6)
Mean area oversizing, % 6.6  10.5 10.9  12.9 0.06
Area undersized (<0%) 37 (30.6) 5 (16.7) 0.268
Area oversizing 0–10% 38 (31.4) 8 (26.7)
Area oversizing 10%–20% 34 (28.1) 12 (40.0)
Area oversizing >20% 12 (9.9) 5 (16.7)
Implantation height (% of stent length
in the aorta)
72.3  14.0 66.5  8.9 0.032
Values are mean  SD or n (%).
TAVR ¼ transcatheter aortic valve replacement; other abbreviations as in Tables 1 and 2.
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810stent extension (p < 0.0001) was associated with a
signiﬁcant decrease in the PPMIR from 25.9% to 12.3%
(p ¼ 0.028) (Figure 6). The mean area oversizing
did not signiﬁcantly differ between the 2 groups
(8.8  10.4% in the ﬁrst 50% of patients) and 6.1 
11.6% in the second 50% of patients (p ¼ 0.13).FIGURE 4 Mean Implantation Height of the Valve (% Aortic)
in Those Patients Who Did Not (No) and Those Who
Required (Yes) a Pacemaker
The error bars indicate the SD.MDCT area undersizing and oversizing percentages
of 0% to 10%, 10% to 20%, and >20% were present
in 16 patients (21.3%), 22 (29.3%), 28 (37.3%), and
9 (12.0%) in the cohort of patients in the ﬁrst period
and in 26 (34.2%), 24 (31.6%), 18 (23.7%), and
8 (10.5%) in the cohort of patients who required a
PPM, with no signiﬁcant differences between groups
(p ¼ 0.20).
DISCUSSION
The present study highlights that the development
of a new TAVR valve design intended to overcome
limitations of the technique may indeed success-
fully reduce 1 complication but at the expense of
increasing another one. Thus, careful clinical eval-
uation of each new valve generation is essential.
The new generation of the balloon-expandable S3
has been suggested to successfully decrease the
rate and degree of paravalvular leakage (14)—one
major concern in TAVR—but the new valve design
has apparently the potential to signiﬁcantly in-
crease the PPMIR required after TAVR. The present
study conﬁrms the marked reduction in PVR with
the new stent design but highlights that this may
indeed occur at the expense of a higher PPMIR.
More importantly, the study demonstrates that
a relatively “high” implantation of the S3 with
little extent of the stent into the LVOT may reduce
this risk and may keep the PPMIR in the same
range as observed with the previous generation of
the XT.
PVR has repeatedly been reported to be associated
with a worse outcome after TAVR with regard to heart
failure rate as well as survival (19). A successful
reduction of PVR by an improved valve design raises
hope to also improve outcome, although this still
needs to be demonstrated.
How much concern is appropriate when such a
decrease in PVR is reached at the expense of an
increasing PPMIR? Again, solid data to answer this
question are lacking. Although controversial data
have been published on the impact of PPM im-
plantation associated with TAVR (20,21), it is un-
likely that PPM implantation does not adversely
affect the long-term outcome in particular when
moving away from very elderly high-risk surgical
patients. A recent analysis of the PARTNER (Place-
ment of AoRtic TraNscathetER Valves) trial and
registry showed that PPMIR was indeed associated
with a longer duration of hospitalization and higher
rates of repeat hospitalization as well as the com-
posite of mortality and repeat hospitalization at
1 year (15).
FIGURE 5 Pearson Correlation Analysis of Implantation
Height and the Cumulative Number of Patients Treated
With the SAPIEN 3 Valve
FIGURE 6 Permanent Pacemaker Implantation Rate and Mean Implantation Height in
the First and Second 50% of SAPIEN 3 Implantations
The columns show the permanent pacemaker implantation (PPMI) rate in the SAPIEN 3
groups after dividing the cohort into the ﬁrst 50% of patients and the second 50% of
patients treated with SAPIEN 3. The mean implantation height of the valve (% aortic)  SD
in each group is shown.
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811To the best of our knowledge, our study is the
ﬁrst comparison of a large group of patients treated
with the S3 and XT demonstrating a signiﬁcant in-
crease in AVCAs and a higher PPMIR with the S3
compared with the XT valve. The pivotal S3 trial
(14) reported a PPMIR of 13.3%. Although this per-
centage is higher than the previously reported 6%
for the XT (10), no comparison of valve generations
is possible from this study nor were predictors of
PPM implantation analyzed. Tarantini et al. (22)
recently reported an increase in PPMIR with the S3
compared with the XT, but their study included
only a very small group of 29 patients treated with
the new-generation valve. Nevertheless, their re-
sults are similar. The PPMIR was similar to ours in
both the S3 (20.7% vs. 19.1%) and XT (10.0% vs.
13.0%). In our study, the higher rate of AVCAs of
any type observed in the S3 group (39.5% vs. 28.9%
in the XT group) was primarily driven by the higher
incidence of third-degree AV block. New-onset
left bundle branch block was observed in 13% of
patients in the S3 group, a lower rate than the 18%
reported in the release study (14), and it was not
associated with a higher PPMIR in the S3 group.
However, the presence of a right bundle branch
block before TAVR was associated with PPM im-
plantation in the S3 group on univariate analysis
(16.1% vs. 3.1%; p ¼ 0.014), but this association
was not signiﬁcant on multivariate analysis. The
degree of MDCT area oversizing by the valve could
play a role in the development of conduction ab-
normalities after TAVR with the previous
XT generation (23). However, in our study, the
MDCT diameter oversizing was not related to the
rate of PPMI in the S3 group, neither on univariateanalysis nor after including it in the multivariate
analysis.
Our study shows that a deeper position of the S3 in
the LVOT is independently associated with a higher
PPMIR after TAVR. This association may also explain
the difference in PPMIR between the S3 and XT. The
stent of the S3 is 3 to 4 mm longer than that of the XT
and tends to reach deeper into the LVOT, particularly
when implanted in a similar way as far as the inten-
ded relationship of aortic to ventricular stent length
is concerned.
The association between implantation height and
PMIR has been well described in studies of TAVR
using the self-expandable CoreValve device (Med-
tronic Inc.) (12). Although the overall PPMIR was
low, such an association was even reported in
studies of the XT as well. Urena et al. (3) reported a
deeper implantation height evaluated by trans-
esophageal echocardiography to be associated with
a higher rate of persistent left bundle branch block,
which in turn determined higher risk of complete
AV block and PPM implantation. Another study
evaluating patients receiving either the XT or the
self-expandable CoreValve also reported an inde-
pendent association between the implantation
height evaluated by callipered angiography with a
higher rate of persistent left bundle branch block
and AV block (4).
PERSPECTIVES
WHAT IS KNOWN? The new stent design of a new
generation of balloon-expandable valves has raised
concerns with regard to a potential increase in
procedure-related pacemaker requirement. Our
results show that the S3 has the potential to markedly
increase the pacemaker rate compared with the XT.
WHAT IS NEW? This pacemaker rate is strongly
related to the implantation height of the stent, and a
change in interventional strategy aiming at a high
implantation resulting in an aortic extension of the
stent >70%may bring the pacemaker rate back to the
range previously observed with the XT.
WHAT IS NEXT? These results may have a major
impact on the recommendations for how to implant
the S3 in order to avoid unnecessarily high pacemaker
rates with their negative impact on long-term
outcome after this intervention.
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812In their small group of 29 patients treated with
the S3, Tarantini et al. (22) found a signiﬁcantly
lower implantation height in those patients
requiring PPM implantation after TAVR. The
maximum extension of the valve into the LVOT
was 8.2  2.0 mm in patients who required a PPM,
and 76% of these had an implantation height of
#60%/40% aortic/ventricular. Patients not requiring
a PPM had a maximal stent extension of 5.0  2.4
mm in the LVOT and an aortoventricular ratio
<60/40% in 47.6%. From their results, the authors
recommend keeping the stent length in the
LVOT <8 mm to avoid development of AV block.
This would result in an aortic percentage of the
stent length >56%, >60%, and >64% for 29-, 26-,
and 23-mm valves, respectively. From our results in
a much larger study group, this position appears to
be still too deep, and an aortic percentage approx-
imately >70% should be intended. Originally, the
company advised positioning the central marker of
the valve within a few millimeters below and above
the insertion points of the valve cusps. However,
to avoid an implantation depth associated with an
increased PMIR, a marker position slightly above
the insertion points is required. Following this
strategy, mean implantation height increased over
time in our series. When dividing the cohort in
the ﬁrst and second 50% of patients, we observed
a signiﬁcant reduction in the PMIR in the second
50% of the patients in the S3 group, in which the
mean implantation height was 75%/25% aortic/ven-
tricular. In this group, the PMIR (12.3%) was similar
to the PMIR in the XT group (12.2%) of our series.
Thus, our study suggests that an optimization of
the implantation technique intending a shorter
extension of the stent into the LVOT signiﬁcantly
reduces the PMIR, reaching values similar to those
found with the previous balloon-expandable valve
generation.
STUDY LIMITATIONS. The study was nonrandomized,
retrospective, and observational. However, baseline
patient characteristics did not signiﬁcantly differ
between the XT and S3 groups, and the results
were conﬁrmed with a propensity score–matching
analysis.
Calcium score was only analyzed in patients
receiving the S3, and it does not provide informa-
tion regarding the distribution of valve calciﬁcation,
and therefore its inﬂuence on the rate of AVCAs,
PPM implantation, and PVR in our study remains
unknown. The reported PMIR in this study repre-
sents the in-hospital occurrence of PPM need. Pa-
tients were monitored for at least 7 days. The meanhospital stay after TAVR was 8 days. PPM implan-
tations after discharge or after patient transfer were
not systematically addressed. Thus, some cases of
late development of AV block and late PPM im-
plantation may have been missed, and the PPMIR
underestimated.
CONCLUSIONS
In this study, the incidence of PPM implantation after
TAVR was signiﬁcantly higher with the S3 than with
the XT, and it was independently associated with
the implantation height of the valve. A progressive
change in the implantation technique toward a higher
implantation resulted in a signiﬁcant reduction in the
PPMIR. The results suggest that the initially observed
increase in PPMIR with the S3 compared with the XT
can apparently be eliminated by optimizing the im-
plantation height of the valve, keeping the extension
of the stent into the LVOT short. It appears advisable
to aim at an aortic extension of >70% of the total
length of the stent.
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